Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 4

Терапия бронхиальной астмы, основанная на биомаркерах
Н.М. Ненашева

References
1. Global Initiative for Asthma. 2018 GINA report. Global strategy for asthma management and prevention. Available at: http://ginasthma.org/2018-gina-report-global-strategy- for-asthma-management-and-prevention/ Accessed 2019 Feb 12.
2. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. The European Respiratory Journal 2000;16(5):802-7.
3. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология 2011;(6):87-93.
4. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. European Respiratory Review 2012 Mar;21(123):66-74.
5. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ. Primary Care Respiratory Medicine 2014 Jun;24:14009.
6. Colice GL, Ostrom NK, Geller DE, Anolik R, Blaiss M, Marcus P, Schwartz J, Nathan RA. The CHOICE survey: high rates of persistent and uncontrolled asthma in the United States. Annals of Allergy, Asthma & Immunology 2012 Mar;108(3):157-62.
7. Chung KF. Personalised medicine in asthma: time for action. Number 1 in the Series “Personalised medicine in respiratory diseases”. Edited by Renaud Louis and Nicolas Roche. European Respiratory Review 2017 Sep 27;26(145). pii: 170064.
8. Pavord ID, Afzalnia S, Menzies-Gow A, Heaney LG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clinical & Experimental Allergy 2017 Feb;47(2):148-60.
9. Ненашева Н.М. Значение биомаркеров в диагностике и терапии бронхиальной астмы. Практическая пульмонология 2017;4:3-9.
10. de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, Bel EH, Ten Brinke A. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Research 2016 May 26;2(2). pii: 00100-2015.
11. Medrek SK, Parulekar AD, Hanania NA. Predictive biomarkers for asthma therapy. Current Allergy and Asthma Reports 2017 Sep;17(10):69.
12. de Groot JC, Ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Research 2015 Sep;1(1). pii: 00024-2015.
13. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. The Journal of Allergy and Clinical Immunology 2004 Jan;113(1):101-8.
14. Schleich FN, Chevremont A, Paulus V, Henket M, Manise M, Seidel L, Louis R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. The European Respiratory Journal 2014 Jul;44(1):97-108.
15. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. The Lancet 2002 Nov;360(9347):1715-21.
16. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosi¬nophilic asthma. The New England Journal of Medicine 2009 Mar;360(10):973-84.
17. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 2011 Nov;184(10):1125-32.
18. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. The New England Journal of Medicine 2013 Jun;368(26):2455-66.
19. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006 Jan;11(4):54-61.
20. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, Wenzel SE, Peters SP, Meyers DA, Bleecker ER; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. Journal of Allergy and Clinical Immunology 2014;133:1557-63.
21. Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity. Trends in Immunology 2017 Dec;38(12):942-54.
22. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clari¬thromycin targets neutrophilic airway inflammation in refractory asthma. American Journal of Respiratory and Critical Care Medicine 2008 Jan;177(2):148-55.
23. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Marks GB, Baraket M, Powell H, Taylor SL, Leong LEX, Rogers GB, Simpson JL. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. The Lancet 2017 Aug;390(10095):659-68.
24. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O’Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P; Study Investigators. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clinical & Experimental Allergy 2012 Jul;42(7):1097-103.
25. Fitzpatrick AM. Biomarkers of asthma and allergic airway diseases. Annals of Allergy, Asthma & Immunology 2015 Nov;115(5):335-40.
26. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. American Journal of Respiratory and Critical Care Medicine 2011 Sep;184(5):602-15.
27. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. American Journal of Respiratory and Critical Care Medicine 2005 Apr;171(8):912-30.
28. Smith AD, Cowan JO, Brasset KP, Filsell S, McLachlan C, Monti-Sheehan G, Peter Herbison G, Robin Taylor D. Exhaled nitric oxide: a predictor of steroid response. American Journal of Respiratory and Critical Care Medicine 2005 Aug;172(4):453-9.
29. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE; BIOAIR investigators. Frequent exacerbators – a distinct phenotype of severe asthma. Clinical & Experimental Allergy 2014 Feb;44(2):212-21.
30. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. The Journal of Allergy and Clinical Immunology 2007 Aug;176(3):231-7.
31. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2005 Oct;172(7):831-6.
32. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, Gibson PG. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. The Lancet 2011 Sep;378(9795):983-90.
33. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effect of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. American Journal of Respiratory and Critical Care Medicine 2013 Apr;187(8):804-11.
34. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosi¬nophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet 2012 Aug;380(9842):651-9.
35. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Benralizumab, an anti-interleukin 5 receptor  monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. The Lancet. Respiratory Medicine 2014 Nov;2(11):879-90.
36. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. The New England Journal of Medicine 2018 Jun;378(26):2486-96.
37. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. The Lancet. Respiratory Medicine 2015 Nov;3(11):849-58.
38. Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. The European Respiratory Journal 2018 Apr 19;51(4). pii: 1702536.
39. Fitzpatrick AM. Severe asthma in children: lessons learned and future directions. The Journal of Allergy and Clinical Immunology In Practice 2016 Jan-Feb;4(1):11-9.
40. Wark PA, McDonald VM, Gibson PG. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma. Respirology 2015 Nov;20(8):1282-4.
41. Jabbal S, Lipworth BJ. Blood eosinophils: the forgotten man of inhaled steroid dose titration. Clinical & Experimental Allergy 2018 Jan;48(1):93-5.
42. Westerhof GA, Korevaar DA, Amelink M, de Nijs SB, de Groot JC, Wang J, Weersink EJ, ten Brinke A, Bossuyt PM, Bel EH. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. The European Respiratory Journal 2015 Sep;46(3):688-96.
43. Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Haanpää J, Niemelä O, Kankaanranta H. Differences between asthma-COPD overlap syndrome and adult-onset asthma. The European Respiratory Journal 2017 May 1;49(5). pii: 1602383.
44. Nadif R, Siroux V, Boudier A, le Moual N, Just J, Gormand F, Pison C, Matran R, Pin I. Blood granulocyte patterns as predictors of asthma phenotypes in adults from the EGEA study. The European Respiratory Journal 2016 Oct;48(4):1040-51.
45. Korevaar DA, Westerhof GA, Wang J, Cohen JF, Spijker R, Sterk PJ, Bel EH, Bossuyt PM. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. The Lancet. Respiratory Medicine 2015 Apr;3(4):290-300.
46. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. The Journal of Allergy and Clinical Immunology 2012 Sep;130(3):647-54.
47. Takahashi K, Meguro K, Kawashima H, Kashiwakuma D, Kagami SI, Ohta S, Ono J, Izuhara K, Iwamoto I. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. The Journal of Asthma 2019 Mar;56(3):236-43.
48. James A, Janson C, Malinovschi A, Holweg C, Alving K, Ono J, Ohta S, Ek A, Middelveld R, Dahlén B, Forsberg B, Izuhara K, Dahlén SE. Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy 2017 Nov;72(11):1753-60.
49. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, Kuwabara K, Tomii K, Otsuka K, Fujimura M, Ohkura N, Tomita K, Yokoyama A, Ohnishi H, Nakano Y, Oguma T, Hozawa S, Nagasaki T, Ito I, Oguma T, Inoue H, Tajiri T, Iwata T, Izuhara Y, Ono J, Ohta S, Tamari M, Hirota T, Yokoyama T, Niimi A, Mishima M. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. The Journal of Allergy and Clinical Immunology 2013 Aug;132(2):305-12.e3.
50. Kanemitsu Y, Ito I, Niimi A, Izuhara K, Ohta S, Ono J, Iwata T, Matsumoto H, Mishima M. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. American Journal of Respiratory and Critical Care Medicine 2014 Aug;190(4):472-4.
51. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. The New England Journal of Medicine 1989 Feb;320(5):271-7.
52. Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, Wenzel SE, Aujla S, Castro M, Bacharier LB, Gaston BM, Bleecker ER, Moore WC; National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute severe asthma research program. The Journal of Allergy and Clinical Immunology 2011 Feb;127(2):382-9.e11-3.
53. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. The New England Journal of Medicine 1991 Oct;325(15):1067-71.
54. Sherrill DL, Lebowitz MD, Halonen M, Barbee RA, Burrows B. Longitudinal evaluation of the association between pulmonary function and total serum IgE. American Journal of Respiratory and Critical Care Medicine 1995 Jul;152(1):98-102.
55. Tajiri T, Matsumoto H, Gon Y, Ito R, Hashimoto S, Izuhara K, Suzukawa M, Ohta K, Ono J, Ohta S, Ito I, Oguma T, Inoue H, Iwata T, Kanemitsu Y, Nagasaki T, Niimi A, Mishima M. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy 2016 Oct;71(10):1472-9.

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]